UGT1A1-guided irinotecan for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether adjusting irinotecan treatment based on a person’s UGT1A1 gene test can improve outcomes for locally advanced rectal cancer. It focuses on people who are about to start (or continue) chemoradiation and do not have cancer spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed by biopsy with rectal adenocarcinoma (a common type of rectal cancer)
- Your cancer is stage T3 or T4 and/or lymph nodes are positive, and your plan includes nCRT (chemoradiation)
- Your scans show no distant metastases (no spread to far-away organs)
- You need to have tumor tissue taken for testing during the study
- You are 18 to 75 years old, and your general health is good enough (ECOG 0 to 2)
- Your UGT1A1 gene test shows either *6 or *28, and you can follow the study plan and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a special form of chemotherapy (irinotecan liposomes) before surgery can help shrink rectal cancer tumors and improve outcomes. It is for people with locally advanced rectal cancer who have not yet had any treatment.
This trial tests whether some people with locally advanced rectal cancer can safely avoid surgery after chemoradiotherapy. If the tumor disappears, patients may be monitored closely instead of having an operation, which could help preserve the anus.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
Hear when a new Rectal Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.